Healthy men and women aged 18-45 years with no comorbidities were randomly assigned , by computer-generated block randomisation ( block size of 14 ) , to receive either one of three escalating doses of the measles-virus-based candidate vaccine ( low dose [ 1510 ( 4 ) median tissue culture infection doses ( TCID50 ) per 005 mL ] , medium dose [ 7510 ( 4 ) TCID50 per 025 mL ] , or high dose [ 3010 ( 5 ) TCID50 per 10 mL ] ) , or the active comparator-Priorix .